B. Hughes

发表

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.

B. Chan, B. Hughes, 2015, Translational lung cancer research.

KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

R. Greil, K. Harrington, A. Psyrri, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial.

M. Stockler, N. Pavlakis, M. Millward, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Hung-Ming Wang, R. Greil, K. Harrington, 2019, The Lancet.

An update: circulating tumor cells in head and neck cancer

B. Hughes, L. Kenny, C. Punyadeera, 2019, Expert review of molecular diagnostics.

Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score

R. Greil, K. Harrington, I. Braña, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CXCR4 and PD-1 Expression in Head and Neck Cancer with Perineural Spread

B. Hughes, Catherine M Barnett, R. Sommerville, 2018, Journal of Neurological Surgery Part B: Skull Base.

Abstract CT119: CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors

S. Loi, M. Hellmann, L. Emens, 2017 .

Impact of sarcopenia and myosteatosis on survival outcomes for patients with head and neck cancer undergoing curative-intent treatment

M. Banks, J. Bauer, B. Hughes, 2022, British Journal of Nutrition.

Dissecting Tissue Compartment-Specific Protein Signatures in Primary and Metastatic Oropharyngeal Squamous Cell Carcinomas

Ahmed M. Mehdi, B. Hughes, J. Monkman, 2022, Frontiers in Immunology.

The changing face of head and neck cancer: are patients with human papillomavirus-positive disease at greater nutritional risk? A systematic review

J. Bauer, A. Edwards, B. Hughes, 2022, Supportive Care in Cancer.

Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma.

F. Simpson, M. Foote, B. Hughes, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Application of circulating tumour cells to predict response to treatment in head and neck cancer

J. Thiery, M. Warkiani, B. Hughes, 2022, Cellular Oncology.

Randomised controlled trial of early prophylactic feeding vs standard care in patients with head and neck cancer

M. Banks, J. Bauer, B. Hughes, 2017, British Journal of Cancer.

Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN)

W. Dougall, M. Smyth, B. Hughes, 2019, Trials.

A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.

M. Stockler, N. Pavlakis, M. Millward, 2013, Lung cancer.

MA 19.03 Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME-Meso Study

M. Socinski, G. Scagliotti, N. Pavlakis, 2017 .

Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma

N. Pavlakis, K. O'Byrne, B. Thapa, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Retrospective analysis of hospital admissions due to immune checkpoint inhibitor‐induced immune‐related adverse events (irAE)

B. Hughes, A. Schmidt, Z. Lwin, 2020, Asia-Pacific journal of clinical oncology.

An analysis of incidental and symptomatic pulmonary embolism (PE) in medical oncology patients

B. Hughes, K. Steinke, M. burge, 2017, Asia-Pacific journal of clinical oncology.

An Occult HPV-Driven Oropharyngeal Squamous Cell Carcinoma Discovered Through a Saliva Test

L. Walsh, B. Hughes, L. Kenny, 2020, Frontiers in Oncology.

Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme

B. Hughes, J. Lickliter, A. Francesconi, 2010, Journal of Clinical Neuroscience.

EGFR mutations in lung cancer: not all equal in the eyes of the immune system?

K. Fong, I. Yang, B. Hughes, 2019, Annals of translational medicine.

Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?

N. Pavlakis, K. O'Byrne, B. Solomon, 2021, Journal for ImmunoTherapy of Cancer.

Concurrent chemoradiation with cisplatin and vinorelbine followed by consolidation with oral vinorelbine in locally advanced non‐small cell lung cancer (NSCLC): the phase II CONCAVE study

B. Hughes, M. Lehman, L. Wockner, 2017, Asia-Pacific journal of clinical oncology.

Validation of an updated evidence-based protocol for proactive gastrostomy tube insertion in patients with head and neck cancer

M. Banks, J. Bauer, B. Hughes, 2016, European Journal of Clinical Nutrition.

Nutrition outcomes following implementation of validated swallowing and nutrition guidelines for patients with head and neck cancer

M. Banks, B. Hughes, L. Ross, 2014, Supportive Care in Cancer.

Evaluation of a speech pathology service delivery model for patients at low dysphagia risk during radiotherapy for HNC

T. Comans, E. Ward, B. Hughes, 2019, Supportive Care in Cancer.

Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer

K. O'Byrne, M. Warkiani, B. Hughes, 2022, Heliyon.

Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma—a phase 3 randomised trial

M. Stockler, N. Pavlakis, K. O'Byrne, 2022, BMJ Open.

Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.

R. Greil, K. Harrington, I. Braña, 2022, Oral oncology.

CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).

M. Stockler, J. Dancey, M. Tsao, 2020 .

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis

A. Hauschild, D. Schadendorf, I. Lowy, 2021, Journal for ImmunoTherapy of Cancer.

The changing face of head and neck cancer: are patients with human papillomavirus-positive disease at greater nutritional risk? A systematic review

J. Bauer, A. Edwards, B. Hughes, 2022, Supportive Care in Cancer.

Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

R. Greil, K. Harrington, A. Psyrri, 2019, Journal of Clinical Oncology.

Prior or concurrent radiotherapy and nivolumab immunotherapy in non–small cell lung cancer

K. O'Byrne, B. Hughes, M. Lehman, 2019, Asia-Pacific journal of clinical oncology.

Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin

B. Hughes, L. Kenny, A. Francesconi, 2017, Head & neck.

Impact of early prophylactic feeding on long term tube dependency outcomes in patients with head and neck cancer.

M. Banks, J. Bauer, B. Hughes, 2017, Oral oncology.

Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients.

J. Nemunaitis, R. Doebele, M. Hellmann, 2017 .

Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673).

R. Govindan, J. Ahn, S. Ou, 2015 .

Swallowing outcomes and PEG dependence in head and neck cancer patients receiving definitive or adjuvant radiotherapy +/- chemotherapy with a proactive PEG: a prospective study with long term follow up.

E. Ward, B. Hughes, T. Brown, 2015, Oral oncology.

Protocol for a randomized controlled trial of early prophylactic feeding via gastrostomy versus standard care in high risk patients with head and neck cancer

M. Banks, J. Bauer, B. Hughes, 2014, BMC Nursing.

Decreased hospital stay and significant cost savings after routine use of prophylactic gastrostomy for high‐risk patients with head and neck cancer receiving chemoradiotherapy at a tertiary cancer institution

M. Appleyard, B. Hughes, L. Tripcony, 2013, Head & neck.

Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging.

L. Mileshkin, R. Hicks, B. Fine, 2014, The oncologist.

Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 Study): an open-label, nonrandomized, multicenter, phase 2 trial.

S. Billan, A. Arance, R. Gutzmer, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

An unusual recurrence of adenosquamous carcinoma of the lung

B. Hughes, D. Godbolt, Khageshwor Pokharel, 2015 .

Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib

G. Hampton, L. Amler, R. Hicks, 2011, Clinical Cancer Research.

Prevalence and Impact of Computed Tomography–Defined Sarcopenia on Survival in Patients with Human Papillomavirus–Positive Oropharyngeal Cancer: A Systematic Review

J. Bauer, A. Edwards, B. Hughes, 2022, Advances in nutrition.

1240PA PHASE 1B STUDY OF THE ANTI-CANCER STEM CELL AGENT DEMCIZUMAB (DEM), PEMETREXED (PEM) & CARBOPLATIN (CARBO) IN PTS WITH 1ST LINE NON-SQUAMOUS NSCLC.

M. Hidalgo, M. Millward, B. Markman, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.

Jie Yang, S. Ou, A. Dingemans, 2017, European journal of cancer.

Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)

J. Schachter, J. Grob, R. Gonzalez, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma

A. Hauschild, D. Schadendorf, C. Chung, 2018, The New England journal of medicine.

J. Schachter, J. Grob, N. Basset-Seguin, 2021, Dermatology and Therapy.

Radiotherapy for cutaneous head and neck cancer and parotid tumours: a prospective investigation of treatment-related acute swallowing and toxicity patterns

Shu Qi Yeo, E. Ward, B. Hughes, 2018, Supportive Care in Cancer.

The ENHANCES study—Enhancing Head and Neck Cancer patients’ Experiences of Survivorship: study protocol for a randomized controlled trial

A. McCarthy, P. Yates, H. Skerman, 2014, Trials.

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

R. Greil, I. Braña, A. Psyrri, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive Biomarkers and Personalized Medicine Evaluation of Circulating Tumor Cells and Circulating Tumor DNA inNon – SmallCell LungCancer : AssociationwithClinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib

G. Hampton, L. Amler, R. Hicks, 2012 .

Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib

B. Solomon, L. Amler, L. Mileshkin, 2011, Clinical Cancer Research.

Imaging , Diagnosis , Prognosis Changes in 18 F-Fluorodeoxyglucose and 18 F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non – Small Cell Lung Cancer Treated with Erlotinib

B. Solomon, L. Amler, L. Mileshkin, 2011 .

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC

M. Hidalgo, M. Millward, B. Markman, 2018, Targeted Oncology.

EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer.

N. Pavlakis, B. Solomon, A. Gill, 2021, Clinical lung cancer.

Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer

T. Marron, Richard A. Miller, J. Luke, 2022, Journal for ImmunoTherapy of Cancer.

Pembrolizumab (P) or P + chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state.

R. Greil, K. Harrington, A. Psyrri, 2020 .

CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells.

G. Kristiansen, J. Madore, J. Landsberg, 2020, Immunity.

Quality-of-life among head and neck cancer survivors at one year after treatment--a systematic review.

S. Chair, C. Chan, B. Hughes, 2012, European journal of cancer.

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.

A. Hauschild, D. Schadendorf, J. Taube, 2022, The New England journal of medicine.

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

R. Govindan, J. Ahn, S. Ou, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and ImmunOtherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma

B. Hughes, L. Kenny, K. Hay, 2021, Radiation Oncology.

Patterns of dysphagia and acute toxicities in patients with head and neck cancer undergoing helical IMRT±concurrent chemotherapy.

E. Ward, B. Hughes, L. Kenny, 2017, Oral oncology.

Improving guideline sensitivity and specificity for the identification of proactive gastrostomy placement in patients with head and neck cancer

B. Hughes, L. Kenny, L. Tripcony, 2016, Head & neck.

Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer.

P. Savas, B. Solomon, B. Hughes, 2013, Journal of thoracic disease.

Development of a core outcome set for cutaneous squamous cell carcinoma trials: identification of core domains and outcomes *

I. Zalaudek, G. Argenziano, C. Longo, 2020, The British journal of dermatology.

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

A. Hauschild, D. Schadendorf, I. Lowy, 2020, Journal for immunotherapy of cancer.

Other novel molecular targets in non-small cell lung cancer: It's not all about EGFR

Ross P Cruikshank, B. Hughes, Ross Cruikshank, 2013 .

Traveling With Cancer: A Guide for Oncologists in the Modern World

M. Khasraw, B. Hughes, M. Hibbert, 2019, Journal of global oncology.

Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.

T. Choueiri, R. Heist, M. Sznol, 2019, Cancer discovery.

Oral HPV16 DNA as a screening tool to detect early oropharyngeal squamous cell carcinoma

I. Frazer, L. Walsh, B. Hughes, 2020, Cancer science.

Comparison of Nutritional and Clinical Outcomes in Patients with Head and Neck Cancer Undergoing Chemoradiotherapy Utilizing Prophylactic versus Reactive Nutrition Support Approaches.

M. Banks, J. Bauer, B. Hughes, 2016, Journal of the Academy of Nutrition and Dietetics.

CCTG BR34: A randomized phase II trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic non-small cell lung cancer.

M. Stockler, J. Dancey, M. Tsao, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up.

A. Hauschild, I. Lowy, R. Gutzmer, 2019, Journal of Clinical Oncology.

Clinical guidance for radioiodine refractory differentiated thyroid cancer

J. Tie, J. Walsh, B. Hughes, 2018, Clinical endocrinology.

Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up.

A. Hauschild, D. Schadendorf, I. Lowy, 2020 .

Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up

A. Hauschild, D. Schadendorf, I. Lowy, 2020 .

Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities

K. O'Byrne, B. Hughes, Z. Lwin, 2017, Asia-Pacific journal of clinical oncology.

A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer

M. Brose, M. Krzyzanowska, B. Konda, 2021, The Journal of clinical endocrinology and metabolism.

Pneumocystis Pneumonia (Pjp) in Lung Cancer Patients

B. Hughes, K. Hay, Z. Lwin, 2016 .

Patients' and doctors' preferences for adjuvant chemotherapy in resected non-small-cell lung cancer: What makes it worthwhile?

M. Stockler, M. Millward, B. Hughes, 2015, European journal of cancer.

New radiotherapy techniques do not reduce the need for nutrition intervention in patients with head and neck cancer

M. Banks, J. Bauer, B. Hughes, 2015, European Journal of Clinical Nutrition.

OA08.02 DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result

M. Stockler, N. Pavlakis, K. O'Byrne, 2018, Journal of Thoracic Oncology.

Randomised trial of radiotherapy with weekly cisplatin or cetuximab in low risk HPV associated oropharyngeal cancer (TROG 12.01) - a Trans-Tasman Radiation Oncology Group study.

R. Fisher, D. Rischin, Lachlan McDowell, 2021, International journal of radiation oncology, biology, physics.

A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer.

N. Pavlakis, B. Solomon, S. Clarke, 2020, Lung cancer.

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

T. Choueiri, R. Heist, M. Sznol, 2019 .

DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma—First results.

M. Stockler, N. Pavlakis, K. O'Byrne, 2018 .

P76.03 Efficacy and Safety of Capmatinib Plus Nivolumab in Pretreated Patients with EGFR Wild-Type Non–Small Cell Lung Cancer

Ying Cheng, E. Felip, J. Wolf, 2021 .

Investigation of p16 status, chemotherapy regimen, and other nutrition markers for predicting gastrostomy in patients with head and neck cancer

M. Banks, J. Bauer, B. Hughes, 2017, Head & neck.

Evaluation of a novel pre-treatment model of nutrition care for patients with head and neck cancer receiving chemoradiotherapy.

M. Banks, J. Bauer, B. Hughes, 2021, Nutrition & dietetics: the journal of the Dietitians Association of Australia.

Helical intensity‐modulated radiotherapy with concurrent chemotherapy for oropharyngeal squamous cell carcinoma: A prospective investigation of acute swallowing and toxicity patterns

E. Ward, B. Hughes, L. Kenny, 2018, Head & neck.

Validated swallowing and nutrition guidelines for patients with head and neck cancer: Identification of high‐risk patients for proactive gastrostomy

M. Banks, B. Hughes, L. Kenny, 2012, Head & neck.

Tube feeding during treatment for head and neck cancer - Adherence and patient reported barriers.

M. Banks, J. Bauer, B. Hughes, 2017, Oral oncology.

Semiqualitative research protocol to explore cancer care workforce perceptions of the health system response to COVID-19 preparations in Southeast Queensland, Australia

B. Chan, B. Hughes, Z. Lwin, 2021, BMJ Open.

Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy

Chin Wee Tan, Q. Nguyen, M. Warkiani, 2023, Frontiers in Immunology.

Enteral nutrition support and treatment toxicities in patients with head and neck cancer receiving definitive or adjuvant helical intensity‐modulated radiotherapy with concurrent chemotherapy

B. Hughes, L. Kenny, A. Pelecanos, 2022, Head & neck.

The ENHANCES study: a randomised controlled trial of a nurse-led survivorship intervention for patients treated for head and neck cancer

A. McCarthy, P. Yates, H. Skerman, 2019, Supportive Care in Cancer.

Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101.

D. Chakrabarti, A. Shaw, E. Felip, 2018 .

M. Brose, M. Krzyzanowska, B. Konda, 2022, Cancer medicine.

Adenosine receptor blockade with ciforadenant +/- atezolizumab in advanced metastatic castration-resistant prostate cancer (mCRPC).

A. Hotson, L. Fong, L. Harshman, 2020 .

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.

M. Stockler, N. Pavlakis, K. O'Byrne, 2020, The Lancet Oncology.

A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and ImmunOtherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma

B. Hughes, L. Kenny, M. Teng, 2021, Radiation oncology.

Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 study

J. Schachter, J. Grob, N. Basset-Seguin, 2019, Annals of Oncology.

Single-cell Spatial Metabolic and Immune Phenotyping of Head and Neck Cancer Tissues Identifies Tissue Signatures of Response and Resistance to Immunotherapy

S. Basu, B. Hughes, O. Braubach, 2023, bioRxiv.

Single institution retrospective review of perioperative chemotherapy in adult and adolescent patients with operable osteosarcoma

S. Paul, A. Hansen, B. Hughes, 2016, Asia-Pacific journal of clinical oncology.

26PPembrolizumab (pembro) for relapsed malignant pleural mesothelioma (MPM): Outcomes in real-life setting in Australia (AUS) and Switzerland (CH)

N. Pavlakis, K. O'Byrne, B. Thapa, 2017 .

Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer.

K. O'Byrne, B. Hughes, Z. Lwin, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Development and Validation of txSim: A Model of Advanced Lung Cancer Treatment in Australia

K. Fong, B. Hughes, K. Canfell, 2023, PharmacoEconomics.

Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients

K. O'Byrne, B. Hughes, L. Kenny, 2021, Frontiers in Oncology.

KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

R. Greil, K. Harrington, A. Psyrri, 2020 .

Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC)

A. Dingemans, S. Ou, F. Barlesi, 2016 .

701 Activating CD73 on B cells as a target for immunotherapy of COVID-19 and viral associated cancers: clinical activity in human papilloma virus positive (HPV) head and neck squamous cell cancers (HNSCC)

J. Sosman, I. Puzanov, J. Janc, 2021, Journal for ImmunoTherapy of Cancer.

Outcomes of anti-PD-1 therapy in mesothelioma and correlation with PD-L1 expression

N. Pavlakis, K. O'Byrne, B. Thapa, 2017 .

Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis

R. Greil, K. Harrington, A. Psyrri, 2020, Bioinformatics, Convergence Science, and Systems Biology.

A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer

B. Keam, B. Jarzab, R. Elisei, 2022, Thyroid : official journal of the American Thyroid Association.

K. O'Byrne, B. Hughes, J. Sanmugarajah, 2018 .

Nintedanib plus Pemetrexed/Cisplatin in Patients with MPM: Phase II Findings from the Placebo-Controlled LUME-Meso Trial

M. Socinski, G. Scagliotti, N. Pavlakis, 2017 .

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC

M. Hidalgo, M. Millward, B. Markman, 2018, Targeted Oncology.

P2.01-50 Thromboembolism in ROS1 Rearranged Non-Small Cell Lung Cancer

N. Pavlakis, S. Clarke, M. Millward, 2018, Journal of Thoracic Oncology.

Patterns of care for stage III non–small cell lung cancer in Australia

S. Kao, B. Chan, B. Hughes, 2019, Asia-Pacific journal of clinical oncology.

DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial.

M. Stockler, M. Zauderer, N. Pavlakis, 2021, Journal of Clinical Oncology.